All In Biotech

Drug Trial Radar · NCT04084314

Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study

Last checked: Nov 20, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

701

Actual

Start

Sep 30, 2019

Primary completion

Feb 23, 2023

Study completion Mar 13, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 67 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 128-week open-label study to assess the long-term safety and tolerabilty of the monoclonal antibody erenumab in migraine patients.

Conditions

  • Migraine
  • Migraine Disorders
  • Migraine Headache

Interventions

  • ErenumabBiological

    Erenumab was supplied as a pre-filled pen (auto-injector) for subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Exposure Adjusted Incidence Rate of AE During Open-label Treatment Epoch Per 100 Subject YearsTime frame: Up to 128 weeks

Locations

75 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Alzenau in Unterfranken, Germany

  • Novartis Investigative Site

    Bad Homburg, Germany

  • Novartis Investigative Site

    Bad Honnef, Germany

  • Novartis Investigative Site

    Bad Saarow, Germany

  • Novartis Investigative Site

    Bayreuth, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Bielefeld, Germany

  • Novartis Investigative Site

    Böblingen, Germany

  • Novartis Investigative Site

    Bochum, Germany

  • Novartis Investigative Site

    Bonn, Germany

  • Novartis Investigative Site

    Bonn, Germany

  • Novartis Investigative Site

    Chemnitz, Germany

  • Novartis Investigative Site

    Cologne, Germany

  • Novartis Investigative Site

    Dillingen, Germany

  • Novartis Investigative Site

    Erbach im Odenwald, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Frankfurt, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Germany

  • Novartis Investigative Site

    Gelsenkirchen, Germany

  • Novartis Investigative Site

    Greifswald, Germany

  • Novartis Investigative Site

    Haar, Germany

  • Novartis Investigative Site

    Halle, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Hoppegarten, Germany

  • Novartis Investigative Site

    Ibbenbueren, Germany

  • Novartis Investigative Site

    Jena, Germany

  • Novartis Investigative Site

    Jülich, Germany

  • Novartis Investigative Site

    Kassel, Germany

  • Novartis Investigative Site

    Kiel, Germany

  • Novartis Investigative Site

    Königstein im Taunus, Germany

  • Novartis Investigative Site

    Leipzig, Germany

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.